Fulltext

Phage Lytic Enzyme Cpl-1 for Antibacterial Therapy in Experimental Pneumococcal Meningitis

Grandgirard, Denis ; Loeffler, Jutta M. ; Fischetti, Vincent A. ; Leib, Stephen L.

In: The Journal of Infectious Diseases, 2008, vol. 197, no. 11, p. 1519-1522

Ajouter à la liste personnelle
    Titre
    • Phage Lytic Enzyme Cpl-1 for Antibacterial Therapy in Experimental Pneumococcal Meningitis
    Auteur
    • Grandgirard, Denis. Institute for Infectious Diseases, University of Bern, Switzerland
    • Loeffler, Jutta M.. Laboratory of Bacterial Pathogenesis, The Rockefeller University, New York, New York
    • Fischetti, Vincent A.. Laboratory of Bacterial Pathogenesis, The Rockefeller University, New York, New York
    • Leib, Stephen L.. Institute for Infectious Diseases, University of Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • The Journal of Infectious Diseases, 2008, vol. 197, no. 11, p. 1519-1522. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:293499
    Summary
    Treatment of bacterial meningitis caused by Streptococcus pneumoniae is increasingly difficult, because of emerging resistance to antibiotics. Recombinant Cpl-1, a phage lysin specific for S. pneumoniae, was evaluated for antimicrobial therapy in experimental pneumococcal meningitis using infant Wistar rats. A single intracisternal injection (20 mg/kg) of Cpl-1 resulted in a rapid (within 30 min) decrease in pneumococci in cerebrospinal fluid (CSF) by 3 orders of magnitude lasting for 2 h. Intraperitoneal administration of Cpl-1 (200 mg/kg) led to an antibacterial effect in CSF of 2 orders of magnitude for 3 h. Cpl-1 may hold promise as an alternative treatment option in pneumococcal meningitis